Clinical Trial Update: A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) [Phase 1]

View source ↗

Summary

Phase 1 study of JNJ-67571244 in relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• JNJ-67571244

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes | Phase 1 | Status: COMPLETED